...
首页> 外文期刊>Respiratory Research >Thymosin β10 promotes tumor-associated macrophages M2 conversion and proliferation via the PI3K/Akt pathway in lung adenocarcinoma
【24h】

Thymosin β10 promotes tumor-associated macrophages M2 conversion and proliferation via the PI3K/Akt pathway in lung adenocarcinoma

机译:胸腺素β10通过肺腺癌的PI3K / AKT途径促进肿瘤相关的巨噬细胞M2转化和增殖

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Abstract Background Thymosin β10 (TMSB10) has been reported to play a protumorigenic role in a majority of solid cancers. However, the existence of TMSB10 in immune microenvironment may contribute to the pathogenesis of lung adenocarcinoma has not been previously explored. Method TAMs-associated TMSB10 expression was evaluated by immunohistochemistry (IHC) in 184 lung adenocarcinomas. Xenograft mice model was established to investigate the effect of TMSB10 shRNA on TAMs phenotypes. The macrophages phenotype associated cytokines IL-6, IL-8, IL-12 and TNF-α were detected by ELISA after treated with TMSB10 shRNA or scramble. Furthermore, the target proteins were detected by immunoblotting. Results We found that high TAMs-associated TMSB10 expression was significantly correlated with the advanced TNM stage and T3/T4 tumor size. And high TAMs-associated TMSB10 expression was significantly correlated with poor overall and progression-free survival of lung adenocarcinoma, acting as an independent prognostic factor for lung adenocarcinoma. Furthermore, we investigated the biological functions of TMSB10 in macrophages in vivo and in vitro. TMSB10 knockdown dramatically reduced TAMs, THP-1 and RAW264.7 cell proliferation, and promoted macrophages phenotype conversion of M2 to M1, and TMSB10 knockdown reduced the levels of p-Akt (Sec473), p-mTOR (Sec2448) and p-p70S6K (Thr389) without effect on Akt, mTOR and p70S6K expression. Conclusions These results demonstrate that TAMs-associated TMSB10 promotes tumor growth through increasing TAMs M2 conversion and proliferation via PI3K/Akt signaling pathway, providing a promising tumor biomarker for predicting prognosis and a potential therapeutic target for lung adenocarcinoma.
机译:据报道,摘要背景胸腺蛋白β10(TMSB10)在大多数固体癌症中发挥突出作用。然而,免疫微环境中TMSB10的存在可能导致肺腺癌的发病机制尚未探讨。方法是通过免疫组织化学(IHC)在184中的184个肺腺癌中评价方法TAMS相关的TMSB10表达。建立了异种移植小鼠模型,以研究TMSB10 shRNA对TAMS表型的影响。用ELISA在用TMSB10 shRNA或争夺后,通过ELISA检测巨噬细胞表型相关细胞因子IL-6,IL-8,IL-12和TNF-α。此外,通过免疫印迹检测靶蛋白。结果我们发现高地相关的TMSB10表达与晚期TNM阶段和T3 / T4肿瘤大小明显相关。和高地相关的TMSB10表达与肺腺癌的整体和无进展生存率差异显着相关,作为肺腺癌的独立预后因素。此外,我们研究了体内和体外巨噬细胞TMSB10的生物学功能。 TMSB10敲低显着减少了TAMS,THP-1和RAW264.7细胞增殖,并促进了M2至M1的巨噬细胞表型转化,并且TMSB10敲低降低了P-AKT(SEC473),P-MTOR(SEC2448)和P-P70S6K的水平。 (thr389)没有对AKT,MTOR和P70S6K表达的影响。结论这些结果表明,通过通过PI3K / AKT信号通路增加TAMS M2转化率和增殖来提高肿瘤生长,提供有前途的肿瘤生物标志物,用于预测肺腺癌的预后和潜在的治疗靶标。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号